Tumoral PD-L1 does not impact time to treatment discontinuation in EGFR mutated non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitor—a Danish cohort study

BACKGROUND: Not all non-small cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) mutations respond equally to therapy with tyrosine kinase inhibitors (TKIs). Programmed death ligand-1 (PD-L1) has previously been speculated as a possible biomarker for treatment outcom...

Descripción completa

Detalles Bibliográficos
Autores principales: Dissing, Julie Gabe, Ulhøi, Maiken Parm, Sorensen, Boe Sandahl, Meldgaard, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9554682/
https://www.ncbi.nlm.nih.gov/pubmed/36248325
http://dx.doi.org/10.21037/tlcr-22-211

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9554682/
https://www.ncbi.nlm.nih.gov/pubmed/36248325
http://dx.doi.org/10.21037/tlcr-22-211

Ejemplares similares